Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-001 in advanced pancreatic cancer
NCT04183478Phase 3Unknown
- Sponsor
- Renji Hospital
- Start
- Sep 2017
- Primary completion
- Mar 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pancreatic ductal adenocarcinoma (PDAC) comparing Best Support Care Plus K-001 with Best Support Care Plus placebo (2 arms). Primary endpoint: Overall Survival. Status: unknown.
02
Drugs
K-001
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04183478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04183478.